Navigation Links
Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
Date:6/10/2013

BURLINGTON, Mass., June 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging therapy on key efficacy endpoints, including time to disease progression and overall survival, has the most influence over surveyed U.S. and European oncologists' prescribing decisions for platinum-resistant advanced ovarian cancer. The emerging agents for this indication—Roche/Genentech/Chugai's Avastin (which is already approved in Europe for recurrent platinum-sensitive ovarian cancer), Amgen/Takeda Pharmaceutical's trebananib, Merck/Endocyte's vintafolide and AstraZeneca's olaparib—are all expected to offer efficacy advantages over currently available therapies used to treat platinum-resistant advanced ovarian cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Decision Base 2013 report entitled Ovarian Cancer (Platinum-Resistant Advanced): Are Emerging Targeted Therapies Poised to Fill the Significant Unmet Need for This Difficult-to-Treat Patient Population?, finds that surveyed U.S. oncologists would prescribe Avastin in combination with either weekly paclitaxel (Bristol-Myers Squibb's Taxol, generics) or Janssen Biotech's Doxil/Caelyx to a total of 55 percent of their drug-treated patients with platinum-resistant advanced ovarian cancer.

The report also finds that surveyed managed care organization (MCO) pharmacy directors are receptive to novel therapies that offer an improvement in progression-free survival (PFS) in this patient population. Based on clinical data and thought-leader opinion, Avastin in combination with chemotherapy is in position to offer the PFS benefit that the majority of surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.

"The platinum-resistant advanced ovarian cancer population represents a patient population with high unmet need," said Decision Resources Senior Analyst Gemma McConnell, Ph.D. "Current treatment consists of a non-platinum chemotherapy monotherapy, which typically result in low tumor response rates and a short progression-free interval. Taking together positive Phase III clinical data and interviewed experts' opinion, Avastin in combination with chemotherapy is poised to address this unmet need."

About Decision Resources
Decision Resources ( www.decisionresources.com ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
2. Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
4. NextDocs Launches QuickStart for Emerging Growth Companies
5. Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
6. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
7. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
8. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
9. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
10. Emerging Precision Medicine Powerhouse Changes Name to Increase Visibility and Overall Awesomeness
11. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
Breaking Medicine Technology:
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... factors of a stroke, which we as a society can control and change. , ... stroke occurs nearly every 40 seconds within the United States. Plus, with an estimated ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... Project offering a new model of care for living and healing, celebrated its ... values: Meaningful Life in a Real Home provided by Empowered Staff. , “This is ...
Breaking Medicine News(10 mins):